Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bevacizumab + Capecitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bevacizumab | Avastin | VEGF Antibody 12 VEGFR Inhibitor (Pan) 36 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01722162 | Phase II | Bevacizumab + Capecitabine | Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | Completed | USA | 0 |
NCT03828227 | Phase III | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine | Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters (COLAGE) | Active, not recruiting | FRA | 0 |
NCT03117972 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (CLavSyn) | Active, not recruiting | FRA | 0 |
NCT04310176 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil Bevacizumab + Fluorouracil + Valproic acid Bevacizumab + Capecitabine + Valproic acid Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION) | Recruiting | ITA | 0 |
NCT00442637 | Phase III | Bevacizumab + Capecitabine | Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma (CAIRO3) | Unknown status | NLD | 0 |
NCT02669173 | Phase I | Bevacizumab + Capecitabine | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT02873195 | Phase II | Bevacizumab + Capecitabine Atezolizumab + Bevacizumab + Capecitabine | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT04188145 | Phase III | Capecitabine Fluorouracil + Leucovorin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine | A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (BEVAMAINT) | Recruiting | FRA | 0 |
NCT05609370 | Phase Ib/II | Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab Bevacizumab + Fluorouracil + LBL-007 Bevacizumab + Fluorouracil Bevacizumab + Capecitabine + LBL-007 + Tislelizumab Bevacizumab + Capecitabine + LBL-007 | A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | Recruiting | USA | AUS | 2 |
NCT03050814 | Phase II | Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | Terminated | USA | 0 |